Target Information

Target General Infomation
Target ID
T93440
Former ID
TTDS00521
Target Name
Interleukin-6 receptor
Synonyms
CD126; IL-6R; IL6R; Membrane glycoprotein 80; gp80
Target Type
Successful
Disease Autoimmune diabetes [ICD10: E08-E13]
Ankylosing spondylitis [ICD9: 720; ICD10: M08.1, M45]
Cutaneous lupus erythematosus [ICD9: 710; ICD10: M32]
Enthesopathy; Type 2 diabetes [ICD9:726, 250; ICD10: M76-M77.9, E11]
Juvenile idiopathic arthritis [ICD9: 714.3; ICD10: M08.0]
Melanoma [ICD9: 172; ICD10: C43]
Multiple myeloma [ICD9: 203; ICD10: C90]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
Severely active rheumatoid arthritis [ICD10: M05-M06]
Function
Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
BioChemical Class
Type I cytokine receptor
Target Validation
T93440
UniProt ID
P08887||P40189
Drugs and Mode of Action
Drug(s) Sarilumab Drug Info Approved Severely active rheumatoid arthritis [889446]
Tocilizumab Drug Info Approved Rheumatoid arthritis [536711], [541938]
CHU Drug Info Registered Enthesopathy; Type 2 diabetes [548663]
CNTO-136 Drug Info Phase 3 Cutaneous lupus erythematosus [524294]
Fezakinumabx Drug Info Phase 3 Rheumatoid arthritis [525300]
SA-237 Drug Info Phase 3 Rheumatoid arthritis [524659]
SAR153191 Drug Info Phase 3 Ankylosing spondylitis [542912], [548704]
Tocilizumab Drug Info Phase 3 Juvenile idiopathic arthritis [536711], [541938]
ALX-0061 Drug Info Phase 2 Autoimmune diabetes [524991], [543089]
SBP-002 Drug Info Terminated Melanoma [548186]
Inhibitor Alpha-D-Mannose Drug Info [551393]
Modulator CHU Drug Info [543592]
FM-101 Drug Info [543592]
Sarilumab Drug Info [556264]
SBP-002 Drug Info [556264]
Tocilizumab Drug Info [531351]
Antagonist SA-237 Drug Info [544364]
Sant7 Drug Info [537114]
SAR153191 Drug Info [549823]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Non-alcoholic fatty liver disease (NAFLD)
Reactome MAPK3 (ERK1) activation
MAPK1 (ERK2) activation
WikiPathways SIDS Susceptibility Pathways
Senescence and Autophagy in Cancer
IL-6 signaling pathway
Differentiation Pathway
Interleukin-6 signaling
References
Ref 524294ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
Ref 524659ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health.
Ref 524991ClinicalTrials.gov (NCT02287922) A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
Ref 525300ClinicalTrials.gov (NCT02531633) Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis.
Ref 536711Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66.
Ref 541938(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881).
Ref 542912(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7999).
Ref 543089(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363).
Ref 548186Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022850)
Ref 548663Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027532)
Ref 548704Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027858)
Ref 889446Drugs@FDA (Edaravone)
Ref 531351Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
Ref 533248The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
Ref 537114Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
Ref 543592(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
Ref 544364IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
Ref 549823Pharma & Vaccines. Product Development Pipeline. April 29 2009.
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.